

# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

#### **SECTION 1. IDENTIFICATION**

Product identifier : Orbifloxacin Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address : Rua Coronel Bento Soares, 530

Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

GHS Classification in accordance with ABNT NBR 14725 Standard

Reproductive toxicity : Category 2

Specific target organ toxicity - :

repeated exposure (Oral)

Category 2 (Eye)

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Eye) through prolonged or

repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.8
 28.09.2024
 785423-00019
 Date of first issue: 28.06.2016

Storage:

P405 Store locked up.

Other hazards which do not result in classification

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS** 

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Acute Tox. (Oral), 5 Repr., 2	>= 3 -< 5
Lactic acid	50-21-5	Acute Tox. (Oral), 5 Acute Tox. (Inhala- tion), 5 Skin Corr., 1C Eye Dam., 1	>= 1 -< 3
Sodium hydroxide	1310-73-2	Met. Corr., 1 Skin Corr., 1A Eye Dam., 1	>= 1 -< 2

**SECTION 4. FIRST AID MEASURES** 

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delaved

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.8
 28.09.2024
 785423-00019
 Date of first issue: 28.06.2016

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

#### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Orbifloxacin	113617-63-3	TWA	0.2 mg/m3 (OEB 2)	Internal
Sodium hydroxide	1310-73-2	С	2 mg/m³	ACGIH

**Engineering measures** : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection : Combined particulates and organic vapor type

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Physical state : suspension

Color : light brown

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

### **SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

**Acute toxicity** 

Not classified based on available information.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 10 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

**Components:** 

Orbifloxacin:

Acute oral toxicity : LD50 (Rat): > 3.000 mg/kg



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.8
 28.09.2024
 785423-00019
 Date of first issue: 28.06.2016

Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2.000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg Symptoms: Vomiting

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 200 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg Application Route: Intramuscular

LD50 (Rat): 233 mg/kg

**Application Route: Intravenous** 

LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Assessment: Corrosive to the respiratory tract. Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Skin corrosion/irritation

Not classified based on available information.

**Product:** 

Species : Rabbit

Result : No skin irritation



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.8
 28.09.2024
 785423-00019
 Date of first issue: 28.06.2016

**Components:** 

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Lactic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : Corrosive after 1 to 4 hours of exposure Remarks : Based on data from similar materials

Sodium hydroxide:

Result : Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

**Product:** 

Species : Rabbit

Result : Mild eye irritation

**Components:** 

Orbifloxacin:

Species : Rabbit

Result : Mild eye irritation
Method : Draize Test

Lactic acid:

Species : Chicken eye

Remarks : Based on data from similar materials

Result : Irreversible effects on the eye

Sodium hydroxide:

Result : Irreversible effects on the eye Remarks : Based on skin corrosivity.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

**Product:** 

Test Type : Magnusson-Kligman-Test

Routes of exposure : Dermal



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

Species : Guinea pig

Result : Not a skin sensitizer.

**Components:** 

Orbifloxacin:

Test Type : Maximization Test

Routes of exposure : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Lactic acid:

Test Type : Buehler Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Sodium hydroxide:

Test Type : Human repeat insult patch test (HRIPT)

Routes of exposure : Skin contact Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: equivocal

Test Type: Mouse Lymphoma

Result: positive

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Cell type: Bone marrow

Application Route: Intraperitoneal injection

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

#### Components:

#### Orbifloxacin:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Remarks : Based on data from similar materials

### Reproductive toxicity

Suspected of damaging the unborn child.

### **Components:**

#### Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

weiaht

Result: No adverse effects.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

**Application Route: Oral** 

Embryo-fetal toxicity.: LOAEL: 333 mg/kg body weight Result: No teratogenic effects., Embryotoxic effects and adverse effects on the offspring were detected only at high ma-

ternally toxic doses

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: NOAEL: 20 mg/kg body weight Embryo-fetal toxicity.: NOAEL: 60 mg/kg body weight Result: No effects on early embryonic development., Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal

body weight gain.

Test Type: Development

Species: Dog

Application Route: Oral

Developmental Toxicity: LOAEL: 2,5 mg/kg body weight Result: Effects on postnatal development., Skeletal malfor-

mations.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Lactic acid:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Mouse

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

**Product:** 

Target Organs : Eye

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

**Product:** 

Species : Dog

NOAEL : 22,5 mg/kg



# **Orbifloxacin Liquid Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 28.09.2024 785423-00019 Date of first issue: 28.06.2016 4.8

LOAEL 37,5 mg/kg Application Route Oral Exposure time 30 Days

**Symptoms** Gastrointestinal disturbance

**Species** Dog LOAEL 75 mg/kg **Application Route** Oral 10 Days Exposure time

**Symptoms** Salivation, Gastrointestinal disturbance, Vomiting

**Species** Cat LOAEL 45 mg/kg **Application Route** Oral Exposure time 30 Days **Target Organs** Eye

**Symptoms** Salivation, Lachrymation, Gastrointestinal disturbance, Liver

disorders

#### **Components:**

#### Orbifloxacin:

**Species** Rat **NOAEL** 20 mg/kg LOAEL 80 mg/kg Oral Application Route 3 Months Exposure time

**Target Organs** Testis, Liver, Kidney, spleen

**Species** Mouse NOAEL 80 mg/kg LOAEL 250 mg/kg **Application Route** Oral Exposure time 3 Months

**Species** Juvenile dog **NOAEL** 50 mg/kg LOAEL 250 mg/kg Application Route Oral Exposure time 14 Days **Target Organs** Heart, Bone

**Symptoms** Gastrointestinal disturbance

Remarks mortality observed

**Species** Juvenile dog NOAEL 2 mg/kg LOAEL 3 mg/kg Application Route Oral Exposure time 90 Days **Target Organs** Bone

Remarks No significant adverse effects were reported

Species Doa 37,5 mg/kg **NOAEL** Oral

Application Route



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.8
 28.09.2024
 785423-00019
 Date of first issue: 28.06.2016

Exposure time : 30 Days

Species : Cat NOAEL : 7.5 mg

NOAEL : 7,5 mg/kg
LOAEL : 22,5 mg/kg
Application Route : Oral
Exposure time : 1 Months

Symptoms : Gastrointestinal disturbance

Lactic acid:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Remarks : Based on data from similar materials

Species : Rat
LOAEL : 886 mg/kg
Application Route : Skin contact
Exposure time : 13 Weeks

**Aspiration toxicity** 

Not classified based on available information.

Experience with human exposure

**Components:** 

Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal

disturbance, liver function change, anaphylaxis, Rash

Remarks: May cause photosensitization.

**SECTION 12. ECOLOGICAL INFORMATION** 

**Ecotoxicity** 

Components:

Lactic acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50: > 10 - 100 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

### Persistence and degradability

#### **Components:**

Lactic acid:

Biodegradability : Result: Not readily biodegradable.

Remarks: Based on data from similar materials

#### Bioaccumulative potential

#### **Components:**

Lactic acid:

Partition coefficient: n-

octanol/water

log Pow: -0,62

Mobility in soil
No data available

Other adverse effects

No data available

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

#### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

**UNRTDG** 

Not regulated as a dangerous good

**IATA-DGR** 

Not regulated as a dangerous good

**IMDG-Code** 



# **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.8
 28.09.2024
 785423-00019
 Date of first issue: 28.06.2016

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

**Domestic regulation** 

ANTT

Not regulated as a dangerous good

Special precautions for user

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans -

(LINACH)

Brazil. List of chemicals controlled by the Federal

Police

: Sodium hydroxide

Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

#### **SECTION 16. OTHER INFORMATION**

Revision Date : 28.09.2024 Date format : dd.mm.yyyy

**Further information** 

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / C : Ceiling limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-



# **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.8 28.09.2024 785423-00019 Date of first issue: 28.06.2016

tem; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances: (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8